AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02098512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~* 42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~* 105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1
Study NCT02098512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
Study NCT02098512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning
Description: Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
Study NCT04266184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT)
Description: For abdominal taping, four I-shaped tapes will be used. Two of them will start from the superior symphisis pubis, follow the rectus abdominis muscle, and finish at the xiphoid process. Other two I-shaped tapes will start from the mid-symphisis pubis, follow the external oblique abdominals, and finish at the spina iliaca anterior superiors.~Symphisis pubis taping will be applied with two I-shaped tapes, by forming a X shape.~For lumbopelvic taping, three I-shaped KTs will be used. Two tapes will be applied bilaterally and longitudinally on the lumbar erector spinal muscles. The third tape will start from one sacroiliac joint and end at the other, vertically to the previous two tapes, forming a H-shape.~All tapings will be applied with 15-25% tension (tape-off tension). KTs will stay three days. They will be removed from the site, and the skin will be checked and cleaned. Then, they will be reapplied for the next three days.
Study NCT04266184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic belt (PB)
Description: The women in this group will use the belts, after adjusting them at a comfortable tension, after getting up the bed in the mornings, during daily activities and walking. Evaluation will be made three days after the first application and they will be asked to continue using it for the second three-day period.
Study NCT04266184 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational program
Description: This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
Study NCT04266184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational program
Description: This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
Study NCT04266184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: This program will include pain neuroscience education and ergonomic education, and will approximately last one hour.
Study NCT00068575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: 3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.
Study NCT00068575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 30 mg/m\^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
Study NCT00068575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 175 mg/m\^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
Study NCT00068575 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
Study NCT02705924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Participants will attend conferences where experts present the state of the art in various domains:~* Latest knowledge in oncogenetics~* Recommendations and morbidity of prophylactic breast surgeries and annexectomy~* Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~* How to perform the periodic breast screening~* Assisted medical procreation and embryo selection~* Importance of nutrition and physical activity as risk modulator~* Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~* Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist.
Study NCT02705924 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychoeducation
Description: Participants will attend conferences where experts present the state of the art in various domains:~* Latest knowledge in oncogenetics~* Recommendations and morbidity of prophylactic breast surgeries and annexectomy~* Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~* How to perform the periodic breast screening~* Assisted medical procreation and embryo selection~* Importance of nutrition and physical activity as risk modulator~* Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~* Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist.
Study NCT04076514 — intervention group
Intervention type: PROCEDURE
Intervention: central neck dissection
Description: dissection of central cervical lymph node grope in low grade papillary thyroid cancer
Study NCT00498160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enriched Hematopoietic Stem Cell Infusion
Description: Enriched Hematopoietic Stem Cell Infusion
Study NCT01839396 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Description: The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
Study NCT01839396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
Study NCT00021151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study NCT03600064 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol
Description: the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (Misotac®; Sigma Pharma, SAE, Egypt).
Study NCT01519596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01519596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01519596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Receive lifestyle-related counseling
Study NCT01519596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Undergo physical activity intervention
Study NCT01519596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive educational materials
Study NCT01519596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Undergo usual care
Study NCT03129451 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome specimens in stool
Description: Analyzing Microbiome specimens in stool
Study NCT05896449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11 PET/CT
Description: The PET/CT image acquisition was performed from the skull to the mid-thigh (3-min per bed position, 3 iterations, 21 subsets) with a CT scan (120 kV, 170mAs reference) with dose modulation for anatomic correlation (CARE dose 4D) and attenuation correction on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) 60 min post injection of \[68Ga\]Ga-PSMA-11 (2 MBq per kg body weight).
Study NCT03883594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted Stepped-care
Description: Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
Study NCT00592033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen from a portable concentrator
Description: 2 l/minute during exercise
Study NCT00777621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restriction
Description: This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
Study NCT00777621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
Study NCT00777621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie Restriction and Exercise
Description: This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
Study NCT04093843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: NeuroStar TMS Therapy
Study NCT04153773 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OCT
Description: The degree of physical disability was assessed by using the Expanded Disability Status Scale (EDSS). The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.~Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) that includes the following tests:~1. Symbol Digit Modalities Test (SDMT) that is used for assessment of information processing speed.~2. California Verbal Learning Test - 2nd edition (CVLT-II) .~3. Brief Visuospatial Memory Test-Revised (BVMT-R)~OCT assessment was performed by spectral domain-optical coherence tomography to assess the retinal nerve fiber layer thickness and macular volume in humans .~Each eye for every patient was assessed by measuring the thickness of RNFL and GCC, respecting presence or absence of the previous history of optic neuritis (ON).
Study NCT02680925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lung protective ventilation
Description: TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
Study NCT02680925 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional ventilation
Description: TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
Study NCT02760979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Denosumab treatment one year after surgery
Study NCT02760979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Serum one year after surgery
Study NCT00887120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir standard dose According to WHO simplified dosing table
Description: * BW 6-7.9 kg: 1.5 mL oral q 12 hr~* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~* BW > 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
Study NCT00887120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)
Description: * BW 6-7.9 kg: 1.0 mL oral q 12 hr~* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~* BW > 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
Study NCT02228720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propel Nova Sinus Implant
Description: Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
Study NCT00130195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Study NCT00130195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00130195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Study NCT00130195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Study NCT00130195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Study NCT00130195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00130195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00130195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00359138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: 5 mg tablet once daily
Study NCT00359138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levocetirizine
Description: 5 mg capsule once daily
Study NCT00359138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine placebo tablet
Description: once daily
Study NCT00359138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desloratadine placebo tablet
Description: once daily
Study NCT00359138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine placebo capsule
Description: once daily
Study NCT00359138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levocetirizine placebo capsule
Description: once daily
Study NCT04526236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methadone Injectable Product
Description: Perioperative use of placebo for pain management and remifentanil during the surgery.
Study NCT04526236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Injectable Product
Description: Perioperative use of placebo for pain management and remifentanil during the surgery.
Study NCT00577109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv on day 1 of each 2 week cycle
Study NCT00577109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m2 iv on day 1 of each 2 week cycle
Study NCT00577109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m2 iv on day 1 of each 2 week cycle
Study NCT00577109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU
Description: 400mg/m2 iv on day 1 of each 2 week cycle
Study NCT00577109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
Study NCT01979536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT01979536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT01979536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01979536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV
Study NCT01979536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT01979536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01979536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01979536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT01979536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV
Study NCT03208764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
Study NCT01538628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpaceOAR System
Description: Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
Study NCT01978821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Study NCT03620890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Protamine Hagedorn (NPH)
Description: NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
Study NCT03620890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir insulin
Description: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
Study NCT02516787 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02516787 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EEG measurement
Description: Electro cortical power in alpha frequency ranges (EEG-LORETA)
Study NCT02516787 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NIRS measurements
Description: Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
Study NCT04946279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual/standard of care
Study NCT04946279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive conversation tool
Study NCT04946279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies - Baseline and follow-up questionnaires
Study NCT04946279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies - Baseline and follow-up questionnaires
Study NCT01999569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole administered daily through the time of ovulation.
Study NCT03409848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)
Study NCT03409848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
Study NCT03409848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
Study NCT02823795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
Study NCT01740960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta-9-tetrahydrocannabinol
Description: During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
Study NCT01740960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
Study NCT02726087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ministernotomy
Description: Partial upper J hemisternotomy trough 4th right intercostal space)
Study NCT02726087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full sternotomy
Description: Conventional full median sternotomy
Study NCT01395199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5mg PO initially; may be reduced to 2.5mg PO if side effects
Study NCT01395199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: 5mg PO initially; may be reduced to 2.5mg PO if side effects
Study NCT03029715 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Total intravenous anaesthesia.